Bombing Gilead

December 1, 2003 By Rebecca Minnich

A July FDA letter cited Gilead reps for pitching the nucleotide analog Viread as “safer” and “more potent” than similar nucleo*side* analogs (NRTIs) and ignoring life-threatening side effects like lactic acidosis and kidney and liver problems—issues familiar to NRTIs. “We take [the complaint] very seriously,” said Gilead’s Amy Flood.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.poz.com/article/Bombing-Gilead-732-6244